What Does the New FDA-Approved Alexander Disease Drug Do?
On September 3, 2026, the FDA approved Zanvastro (zilganersen), the first drug shown in a controlled trial to slow Alexander disease itself rather than manage its symptoms. In the pivotal 54-patient study, quarterly spinal injections kept treated patients walking measurably better than untreated ones at about a year. It isn't a cure, and the delivery is a lumbar puncture every 12 weeks for life. But for families who until now had only supportive care, the ceiling on this disease has moved for the first time in decades.
Alexander disease is a genetic leukodystrophy. About 95% of cases come from dominant mutations in GFAP, the gene for the main structural protein of astrocytes. The abnormal protein clumps into deposits called Rosenthal fibers inside those astrocytes, which then stop supporting the surrounding white matter. Infants develop seizures, big heads, and lose motor milestones. Children and adults get progressive weakness, gait problems, and trouble swallowing and breathing. Until this month, treatment was symptom control and nothing else.
A drug that turns down the gene itself
Zanvastro is an antisense oligonucleotide: a short piece of engineered nucleic acid that binds GFAP messenger RNA in astrocytes and marks it for degradation. Less messenger RNA means less GFAP protein, which means fewer Rosenthal fibers and less of the stress response that pushes astrocytes into a reactive, dysfunctional state. GFAP knockout mice do not develop Alexander disease, so the problem is too much of the abnormal protein, not too little of a normal one. Turning production down is the right lever.
This is the same class of drug as nusinersen for spinal muscular atrophy and tofersen for SOD1 ALS. It is not gene therapy. Nothing about your DNA changes, and the effect wears off as the drug clears, which is why dosing continues for life.
What the trial actually showed
The pivotal study was a randomized, double-blind Phase 1-3 trial in 54 patients ages 1.5 to 53, across 13 sites in 8 countries. Small by cardiology standards, large for a disease that affects roughly one person in a million to one in three million. Patients got Zanvastro or control, and the main question was whether their walking held up better a year in.
In patients age 5 and older, treated patients walked about a third faster on the 10-Meter Walk Test at Week 61 than controls, and the difference was statistically significant. In children ages 2 to 4, treated kids gained ground on the Gross Motor Function Measure. Safety events were mostly mild to moderate, and serious events were less common in the Zanvastro arm than in control. The most common adverse reactions were vomiting, back pain, cough, headache, and post-lumbar puncture syndrome. Aseptic meningitis was reported, including one serious case that recurred when the drug was restarted.
Two qualifiers. The result is stabilization, not reversal: patients on the drug didn't get lost function back, they held onto more of what they had. And it is a real clinical outcome, not just a biomarker. That distinction matters because the antisense field has been burned before. Tofersen in SOD1 ALS lowered its target protein and neurofilament light chain but missed its primary functional endpoint in the pivotal trial. BIIB078 in C9orf72 ALS lowered its target and helped no one, and was discontinued. Jacifusen in FUS-ALS knocked its neurodegeneration marker down sharply while most patients kept declining. Zanvastro is the first Alexander-directed drug to show, in a controlled comparison, that patients did something measurably better.
Who it is for and how it is given
| Feature | Detail |
|---|---|
| Age eligibility | Pediatric and adult patients with genetically confirmed Alexander disease |
| Dose and route | 50 mg intrathecal injection every 12 weeks, for life |
| Trial size and design | Randomized, double-blind Phase 1-3; 54 patients ages 1.5 to 53; 8 countries |
| Efficacy, ages 5 and up | About a third faster gait on the 10-Meter Walk Test vs control at Week 61 |
| Efficacy, ages 2 to 4 | Improvement on the Gross Motor Function Measure (GMFM-88) |
| Most common adverse reactions | Vomiting, back pain, cough, headache, post-lumbar puncture syndrome |
| Serious safety signal | Aseptic meningitis, including one serious case that recurred on rechallenge |
| US price | Not disclosed at approval; availability expected within weeks |
The drug goes into the spinal fluid by lumbar puncture, four times a year, indefinitely. That's the same route as nusinersen in spinal muscular atrophy, and it's generally tolerated, but it isn't trivial. Someone has to do the LP, the child or adult has to sit through it, and post-puncture headache is common enough to plan for. Aseptic meningitis, an inflammatory reaction in the fluid around the brain and spine, is the signal to watch: one serious case in the trial came back when the drug was restarted, so any suggestive symptoms after a dose deserve fast attention.
What is still unknown
The trial ran to Week 61. Whether the gait-speed advantage grows, holds, or fades over five and ten years is what the open-label extension is built to answer, and that answer isn't in yet. The 54 patients covered ages 1.5 to 53, but the most severe end of the disease, infantile-onset patients with the R239 GFAP variant, are the hardest to help and still the most in need. How well Zanvastro works for that group specifically isn't yet clear.
Cost is the other open question. Ionis had not disclosed a US list price at approval, and payer coverage decisions haven't been made. Access programs are launching alongside the drug, and ex-US rights sit with Recordati. Expect these details to sharpen over the coming weeks.
What this means for a family facing Alexander disease
If someone in your family has a genetically confirmed GFAP mutation and Alexander disease, this changes the conversation. Until now there was no drug for the disease itself. Now there is one, with controlled-trial evidence that treated patients walked measurably better than untreated ones a year in. The next step is a referral to a leukodystrophy specialist who can weigh the specific GFAP variant, current function, and rate of decline against the tradeoff of quarterly lumbar punctures and the aseptic meningitis risk.
Zanvastro isn't a cure. Patients didn't regain lost function; they lost less of what they had. The injections are into the spine, they continue for life, and the price is still unwritten. But for a disease that had no disease-modifying option at all last month, a drug aimed at the cause, with a clinical win in a randomized trial, is the first time in decades the ceiling has moved.